The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation1
Abstract
Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we report that 1) anandamide and 2-AG inhibit the nerve growth factor (NGF)-induced proliferation of HBCCs through suppression of the levels of NGF Trk receptors; 2) inhibition of PRLr levels results in inhibition of the proliferation of other PRL-responsive cells, the prostate cancer DU-145 cell line; and 3) CB1-like cannabinoid receptors are expressed in HBCCs and DU-145 cells and mediate the inhibition of cell proliferation and Trk/PRLr expression. Beta-NGF-induced HBCC proliferation was potently inhibited (IC50 = 50-600 nM) by the synthetic cannabinoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but not by the anandamide congener, palmitoylethanolamide, or the selective agonist of CB2 cannabinoid receptors, BML-190. The effect of anandamide was blocked by the CB1 receptor antagonist, SR141716A, but not by the CB2 receptor antagonist, SR144528. Anandamide and HU-210 exerted a strong inhibition of the levels of NGF Trk receptors as detected by Western immunoblotting; this effect was reversed by SR141716A. When induced by exogenous PRL, the proliferation of prostate DU-145 cells was potently inhibited (IC50 = 100-300 nM) by anandamide, 2-AG, and HU-210. Anandamide also down-regulated the levels of PRLr in DU-145 cells. SR141716A attenuated these two effects of anandamide. HBCCs and DU-145 cells were shown to contain 1) transcripts for CB1 and, to a lesser extent, CB2 cannabinoid receptors, 2) specific binding sites for [3H]SR141716A that could be displaced by anandamide, and 3) a CB1 receptor-immunoreactive protein. These findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential negative effectors of PRL- and NGF-induced biological responses, at least in some cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
Self-citationSR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Nerve growth factor: from neurotrophin to neurokine
Levi-Montalcini, R., Skaper, S. D., Dal Toso, R., Petrelli, L., & Leon, A. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10058-8 · Cited by 686
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., & Di Marzo, V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8375 · Cited by 413
Self-citationBiosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes
Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L., & Di Marzo, V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3315 · Cited by 369
Self-citationDi Marzo, V. (1998) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(98)00042-3 · Cited by 312
Self-citationDi Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., & Kunos, G. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00631.x · Cited by 296
Self-citationClevenger, C. V., Chang, W. P., Ngo, W., Pasha, T. L., Montone, K. T., & Tomaszewski, J. E. (1995) · PubMed Central · Cited by 252
Melck, D., Bisogno, T., De Petrocellis, L., Chuang, H.-H., Julius, D., Bifulco, M., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1105 · Cited by 188
Self-citationExpression of functional trk protooncogene in human monocytes.
Ehrhard, P. B., Ganter, U., Stalder, A., Bauer, J., & Otten, U. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5423 · Cited by 184
Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia
Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00451.1998 · Cited by 182
Function of Cannabinoid Receptors in the Neuroendocrine Regulation of Hormone Secretion
Murphy, L. L., Muñoz, R. M., Adrian, B. A., & Villanúa, M. A. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0224 · Cited by 176
Prolactin Signaling in Mammary Gland Development
Hennighausen, L., Robinson, G. W., Wagner, K.-U., & Liu, X. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7567 · Cited by 172
Djakiew, D., Delsite, R., Pflug, B. R., Wrathall, J. R., Lynch, J. H., & Onoda, M. (1991) · PubMed · Cited by 140
Trick or treat from food endocannabinoids?
Marzo, V. D., Sepe, N., PETROCELLIS, L. D., Berger, A., Crozier, G. L., Fride, E., & Mechoulam, R. (1998) · Nature · doi:10.1038/25267 · Cited by 130
Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines
Fuh, G., & Wells, J. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13133 · Cited by 128
Cannabinoid Transmission and Pain Perception
Martin, B. R., & Lichtman, A. H. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0218 · Cited by 121
Nerve Growth Factor Is Mitogenic for Cancerous but Not Normal Human Breast Epithelial Cells
Descamps, S., Bourhis, X. L., Delehedde, M., Boilly, B., & Hondermarck, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16659 · Cited by 117
Cardiovascular actions of cannabinoids and their generation during shock
Wagner, J. A., Varga, K. R., & Kunos, G. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050287 · Cited by 111
Pancreatic β cells synthesize and secrete nerve growth factor
Rosenbaum, T., Vidaltamayo, R., Sánchez-Soto, M. C., Zentella‐Dehesa, A., & Hiriart, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7784 · Cited by 109
New class of potent ligands for the human peripheral cannabinoid receptor
Gallant, M., Dufresne, C., Gareau, Y., Guay, D., Leblanc, Y., Prasit, P., Rochette, C., Sawyer, N., Slipetz, D. M., Tremblay, N. M., et al. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00426-x · Cited by 101
Bisogno, T., Katayama, K., Melck, D. J., Ueda, N., PETROCELLIS, L. D., Yamamoto, S., & Marzo, V. D. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2540634.x · Cited by 95
Self-citationIdentification of Endocannabinoids and Cannabinoid CB1 Receptor mRNA in the Pituitary Gland
González, S. R., Manzanares, J., Berrendero, F., Wenger, T., Corchero, J., Bisogno, T., Romero, J., Fuentes, J. A., Marzo, V. D., Ramos, J. A., et al. (1999) · Neuroendocrinology · doi:10.1159/000054468 · Cited by 93
Self-citationFormation of N-Acyl-phosphatidylethanolamines and N-Acylethanolamines
Hansen, H. S., Lauritzen, L., Moesgaard, B., Strand, A. M., & Hansen, H. H. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00396-1 · Cited by 85
The saga of the nerve growth factor.
Levi‐Montalcini, R. (1998) · PubMed · Cited by 67
The Saga of the Nerve Growth Factor: Preliminary Studies, Discovery, Further Development
Levi‐Montalcini, R. (1997) · World Scientific series in 20th century biology · doi:10.1142/3051 · Cited by 65
Pflug, B. R., & Djakiew, D. (1998) · Molecular Carcinogenesis · Cited by 65
Sinha, D., Bonner, T. I., Bhat, N. R., & Matsuda, L. A. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00181-1 · Cited by 55
Prolactin, growth hormone and the immune system in humans
Velkeniers, B., Doğusan, Z., Naessens, F., Hooghe, R. J., & Hooghe-Peters, E. L. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050239 · Cited by 51
Failure of cannabinoid compounds to stimulate estrogen receptors
Ruh, M. F., Taylor, J. A., Howlett, A. C., & Welshons, W. V. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00659-4 · Cited by 44
Kaminski, N. E. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00284-7 · Cited by 31
Morinobu, S., Fujimaki, K., Okuyama, N., Takahashi, M., & Duman, R. S. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722198.x · Cited by 26
A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors.
Ueda, N., Goparaju, S. K., Katayama, K., Kurahashi, Y., Suzuki, H., & Yamamoto, S. (1998) · PubMed · Cited by 23
Arachidonate—Phospholipid Remodeling and Cell Proliferation
Chilton, F. H., Surette, M. E., & Winkler, J. D. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-0179-8_28 · Cited by 19
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., & Di Marzo, V. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105247 · Cited by 568
Self-citationThe cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Metadata
- Authors
- Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M., & Di Marzo, V.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2000-01-01
- Volume
- 141
- Issue
- 1
- Pages
- 118-126
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1986829891
- Cited by
- 265
- References
- 40
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.